The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,737 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Yale University to develop gene therapy approaches to eliminate the HIV reservoir in people living with HIV. Specifically, the project aims to engineer adeno-associated viral (AAV) vectors to deliver a recombinase enzyme called BREC1 that can target and remove HIV DNA sequences integrated into host cells. The research also seeks to develop an enhanced BREC1 variant called BREC1-OFF that can epigenetically silence HIV transcription. These engineered AAV vectors will be evaluated in humanized mouse models to assess their ability to inactivate peripheral and central nervous system HIV reservoirs containing diverse viral isolates. The project has a period of performance from July 2024 through June 2029.
Generated 1/28/25, 7:54 AM